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ABSTRACT
Objectives To summarise the occurrence of congenital 
Zika syndrome (CZS) in Latin America and the Caribbean 
from 2015 to 2017 using two outcome measures derived 
from infectious disease surveillance reports and to assess 
the completeness of these reports.
Design Surveillance study.
Setting Pan American Health Organization (PAHO)/WHO 
epidemiology reports on confirmed and suspected Zika 
virus infection and cases of CZS.
Participants Populations of 47 countries in the South and 
Central Americas, Mexico and the Caribbean.
Primary and secondary outcome measures The number 
of CZS cases per 1000 births (using 2016–2017 births as a 
denominator) and the number of CZS cases per 1000 births in 
women with Zika virus infection during pregnancy.
Results By 4 January 2018, 548623 suspected and 
239063 confirmed Zika virus infections had been reported 
to PAHO/WHO from 47 countries. In 25 countries, over 
80% of infections were reported as suspected. There were 
3617 confirmed CZS cases in 25 countries; 2952 (82%) 
had occurred in Brazil. The number of CZS cases per 
1000 births varied considerably with Brazil and several 
Caribbean island communities (Puerto Rico, St Martin, 
Martinique, Guadeloupe and Grenada) having the highest 
CZS prevalence above 0.5 per 1000 births. Analysing the 
number of CZS cases per 1000 births in women infected 
with Zika virus during their pregnancy highlighted the 
inaccuracies of the data, with Venezuela likely to have had 
severe under- reporting of CZS.
Conclusions Expressing data on CZS in relation to 
total births, rather than as absolute numbers, better 
illustrates the burden of disease, providing that under- 
reporting of CZS is not too severe. Data on infections 
in pregnant women enable potential under- reporting of 
CZS to be identified. Both measures are recommended 
for future PAHO/WHO publications. Evidence of severe 
under- reporting of Zika virus infections and CZS makes 
interpretation of the data and comparisons between 
countries challenging.
INTRODUCTION
In 2015 in North East Brazil, a sudden increase 
in cases of microcephaly were reported after 
the introduction of Zika virus into Brazil.1 
Since then it has been established that Zika 
virus infection in the first trimester of preg-
nancy does increase the risk of the fetus 
having microcephaly.2 Several studies have 
subsequently characterised additional brain 
abnormalities associated with Zika virus infec-
tion during pregnancy and the diagnosis of 
congenital Zika syndrome (CZS) has been 
defined.3–5 There is uncertainty about the 
risk of CZS given a woman is infected with 
Zika virus in the first trimester with one study 
reporting the risks of CZS3 and three studies 
reporting the risks of microcephaly.6–8 Micro-
cephaly is not always present in CZS and 
therefore the prevalence of microcephaly in 
women with first trimester Zika virus infec-
tions will be lower than the prevalence of 
CZS.9 A study of women in America who 
were pregnant and had evidence of Zika virus 
infection during pregnancy (both symptom-
atic and asymptomatic) found that 60 per 
1000 pregnancies were diagnosed with CZS.3 
A case- control study comparing neonates in 
Strengths and limitations of this study
 ► A strength is that surveillance data from every 
country in Latin America and the Caribbean were 
analysed.
 ► A further strength is that the number of congenital 
Zika syndrome cases were population- weighted by 
the number of births, which is not regularly done in 
Pan American Health Organization/WHO reports, and 
which gives a better idea of the disease burden.
 ► A limitation is that the publicly available data do 
not include the numbers of people in a population 
who were tested (including the numbers of pregnant 
women), and the indication for testing, which would 
enhance the interpretation of the reported incidence 
of Zika virus.
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Recife Brazil with microcephaly with controls without esti-
mated that the relative risk of microcephaly given Zika 
virus infection during pregnancy was 73.1.6 If the preva-
lence of microcephaly in women without Zika virus infec-
tions is as estimated by Orioli et al at 0.44 per 1000,10 a 
relative risk of 73.1 is equivalent to an absolute risk of 
around 32 per 1000 births to women with Zika virus infec-
tions.3 Cauchemez et al retrospectively analysed the Zika 
virus outbreak in French Polynesia and estimated that the 
risk of microcephaly from infection in the first trimester 
was 9.5 per 1000 women infected in the first trimester.7 
Brady et al used data from Brazil to estimate that 4 per 
1000 pregnancies infected with Zika virus in the first two 
trimesters would result in a case of microcephaly.8 In 
summary, estimates of the risk of microcephaly or CZS 
given the mother was infected with Zika virus during 
pregnancy vary from 4 per 1000 (the lowest estimate for 
microcephaly) to up to 60 per 1000 births for CZS.
The aim of this study was to summarise the occurrence 
of CZS in Latin America and the Caribbean from 2015 
to 2017 using the number of CZS cases per 1000 births 
and the number of CZS cases per 1000 births in women 
with Zika virus infection during pregnancy. These two 
measures can be derived from infectious disease surveil-
lance reports and provide information about the burden 
of disease and the completeness of the surveillance 
reports.
METHODS
Since May 2015, Pan American Health Organization 
(PAHO)/WHO have reported data on the spread of 
the Zika virus in all countries in Latin America and the 
Caribbean.11 The weekly reports include the cumulative 
numbers of reported Zika virus cases (suspected and 
confirmed), the incidence rates per 1000 people, the 
numbers of deaths among Zika infection cases and the 
numbers of confirmed CZS cases.
Data were taken from the PAHO/WHO publications 
of cumulative cases available on the website (http://www. 
paho. org/ data/ index. php/ en/? option= com_ content& 
view= article& id= 524& Itemid=) up until January 2018 
(accessed 8 October 2020).
A series of reports published on 25 September 2017 
from all countries and territories with autochthonous 
transmission of Zika virus in the Americas provided addi-
tional information on the number of pregnant women 
with suspected and confirmed Zika virus infections up 
until week 35 in 2017. These data were downloaded 
from the website: https://www. paho. org/ hq/ index. php? 
option= com_ content& view= article& id= 11603: countries- 
and- territories- with- autochthonous- transmission- of- zika- 
virus- in- the- americas- reported- in- 2015- 2017& Itemid= 
41696& lang= en (accessed 3 January 2020). Several coun-
tries only reported pregnancies in 2016 and hance were 
likely to have excluded some infected pregnancies occur-
ring in 2017.
Data from Canada, the USA and Bermuda were 
excluded—only countries in the South and Central Amer-
icas, Mexico and the Caribbean were analysed. Apart from 
in Brazil, no cases of CZS were reported in 2015—they 
were all reported in 2016 and 2017. Therefore, we calcu-
lated the CZS per 1000 births using the total number of 
births in 2016 and 2017. The numbers of live births occur-
ring during 2016 and 2017 were obtained in each country 
from the United Nations Demographic Yearbook 2017.12 
In the following countries, the numbers of births were 
only available for earlier years and the numbers occurring 
in 2016–2017 were estimated to be twice that in the most 
recent year of data available: Honduras (2012), Haiti 
(2013), Grenada (2014), Trinidad and Tobago (2015), El 
Salvador (2015) and Guyana (2015).
The PAHO/WHO case definitions for suspected and 
confirmed Zika cases and CZS that were communicated 
to the member states and were used to report cases 
within the International Sanitary Regulations are given 
at http://www. paho. org/ hq/ index. php? option= com_ 
content& view= article& id= 11117& Itemid= 41532& lang= 
en (accessed 22 May 2020).
Statistical analysis
The number of CZS cases per 1000 births was calculated 
to give a population- adjusted measure of the relative size 
of the CZS epidemic in each country, as well as a measure 
of the proportion of births affected relative to other peri-
natal problems.
Island communities have been reported to often expe-
rience much higher infection rates than larger mainland 
communities13 and therefore it might be expected that 
the number of CZS cases per 1000 births would be higher 
on islands. To investigate this, a binomial regression 
model was fitted with each country as a random effect and 
island as a fixed effect.
Each country reported both suspected and confirmed 
Zika virus infections. Main analyses reported are based 
on both confirmed and suspected cases, but analyses 
including only confirmed cases were also performed and 
are compared where relevant.
The number of pregnant women who were infected 
with the Zika virus during their pregnancy was obtained 
from individual country reports on 25 September 2017 
covering all reports up until week 35 of 2017. Some 
countries reported both suspected and confirmed cases 
separately, while other countries reported suspected 
and confirmed cases in total or either only suspected 
or confirmed cases. The total number of suspected and 
confirmed cases was analysed and if this was not avail-
able the number of cases reported was used regardless of 
whether they were suspected or confirmed. The number 
of CZS cases per 1000 women who were infected with 
the Zika virus during their pregnancy was calculated and 
will be referred to as CZS cases per infected pregnancies. 
This measure would be expected to be around 4–60 per 
1000 pregnancies with differences highlighting possible 
reporting issues.
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Linear associations between variables were quantified 
using Spearman’s rho rank correlation coefficients.
RESULTS
Table 1 shows that by the 4 January 2018, 548623 
suspected Zika virus infections and 239063 confirmed 
Zika virus infections had been reported to PAHO/WHO. 
There were 3617 confirmed CZS cases, of which the 
largest numbers of cases were reported in Brazil (2952 
cases; 82%) and Colombia (248; 7%).
Figure 1 compares the number of CZS cases per 1000 
births with the incidence rate of Zika virus infections 
(confirmed and suspected). The two measures are 
linearly related (spearman’s rho=0.64, p=0.008) as is 
expected as a higher incidence of Zika virus would be 
expected to lead to a higher birth prevalence of CZS. 
However, there is much variation in the number of CZS 
cases per 1000 births not explained by the incidence of 
Zika virus in the population. The random effects model 
estimated that countries that are islands have 82% (95% 
CI 54% to 116%) higher rates of CZS per 1000 births than 
non- island communities. Haiti is the exception with only 
1 CZS case reported out of over 3000 Zika virus infec-
tions, indicating under- reporting of CZS. French Guiana, 
Honduras, El Salvador, Nicaragua, Mexico and Argen-
tina also have lower number of CZS cases per 1000 births 
than might be expected due to their reported incidence 
of Zika virus infections, also indicating under- reporting 
of CZS. The correlation between the birth prevalence 
and the incidence of Zika virus is weaker (spearman’s 
rho=0.48, p=0.02) if only confirmed Zika virus infec-
tions are analysed (data not shown). This can be partly 
explained by several countries having over 90% of their 
cases suspected rather than confirmed and three coun-
tries having no confirmed cases (Martinique, Haiti and 
Venezuela) indicating that in these countries Zika virus 
infections although they are suspected are often not 
confirmed. Another explanation could be differential 
reporting of CZS, which we know occurred with Brazil 
being more likely to diagnose CZS than other countries. 
Table 1 shows that four countries had over 6000 Zika virus 
infections and yet reported no cases of CZS (Venezuela, 
Jamaica, Peru and Curacao) suggesting potential under-
reporting of CZS in these countries.
Table 2 shows that 36 025 pregnancies were reported 
to have been confirmed as having been infected with 
Zika virus, with 32% of these being in Brazil and 18% 
in Colombia. A total of 71 230 pregnant women were 
reported as having confirmed or suspected Zika virus 
infections (assuming that the number of suspected or 
confirmed cases is equal to the number of confirmed 
cases in countries only reporting confirmed cases); 37% 
in Brazil and 28% in Colombia.
Figure 2 and table 2 present the number of CZS cases 
per 1000 women who were infected with Zika virus 
during their pregnancy for each country compared with 
the reported values from previous studies of between 4 
and 60 CZS cases per 1000 pregnant women with Zika 
virus.3 6–8 Many countries do have a prevalence close to 
these values. Slightly higher rates (such as in Brazil) may 
suggest more extensive reporting of CZS than of infected 
pregnancies, or the use of wider microcephaly definitions 
earlier in the epidemic. In Argentina, there were five 
cases of CZS reported and only five pregnant women were 
reported as being infected with Zika virus indicating that 
reporting only occurred when CZS was confirmed and 
therefore their rate of 1000 CZS per 1000 pregnancies 
is clearly incorrect (and not plotted in figure 2). Three 
other countries reported at least one case of CZS, but did 
not report any infected pregnancies (Guyana, Grenada 
and Suriname). Several countries such as French Guiana, 
Mexico and Nicaragua have much lower values indicating 
that cases of CZS were being under- reported. This can 
be explained for Nicaragua by the fact that they reported 
infected pregnancies only up until week 1 of 2017. Four 
countries in figure 2 reported >200 pregnant women 
having Zika virus infections (Venezuela (3463), Jamaica 
(712), Peru (279) and the Virgin Islands (USA) (286)) 
and yet reported no cases of CZS. The upper CI being 
around 1 suggests under- reporting of CZS in Venezuela, 
but the numbers of infected pregnancies are too small to 
be informative in the other countries. Haiti only reported 
infected pregnancies up until week 21 of 2016. Figure 2 
indicated that Haiti might have under- reported CZS cases 
and therefore figure 2 indicates that they are also likely 
to have under- reported the number of infected pregnant 
women as the ratio of the two values is reasonable.
Figure 3 shows the number of pregnant women 
who were infected with Zika virus per 1000 births and 
compares this with the reported incidence of Zika virus 
in the population. The majority of countries were above 
the line of equality indicating that infections in pregnant 
women were more likely to be reported than infections 
in the rest of the population. This was likely to be due to 
pregnant women being more likely to be tested for Zika 
virus infection, since they are the high- risk segment of 
the population. The countries below the line of equality 
were perhaps under- reporting the numbers of pregnant 
women with Zika virus infection, particularly Haiti, Belize 
and Saint Vincent and the Grenadines who only reported 
infected pregnancies in 2016 not in 2017.
Zhang et al14 used data from a study in Bahia in Brazil 
from October 2014 to February 201615 and data from a 
study of the 2013 Zika virus outbreak in French Polynesia13 
to develop a global stochastic epidemic model to analyse 
the spread of the Zika virus (ZIKV) in Latin America 
and the Caribbean. Table 3 compares their predictions 
with the reported figures. The agreement is reasonable 
for Brazil, Colombia and Puerto Rico, but much higher 
for Mexico, El Salvador, Honduras, Haiti and Venezuela. 
These later countries are all countries which our analysis 
has indicated have under- reporting of CZS cases. This 
provides further indication that the reporting to PAHO/
WHO is not sufficiently accurate to validate prediction 
models in some countries.
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Table 1 Zika virus infections and CZS cases reported to PAHO/WHO by countries in the South and Central Americas, Mexico 
and the Caribbean, 2016 – 2017* and the estimated number of CZS cases per 1000 births to pregnant women with Zika virus
Country
Zika virus infections† CZS
Population 
(’000) in 
2016/17
Annual 
births in 
2016/17‡Suspected
Confirmed 
(including 
imported)
% 
Suspected
Total 
suspected 
and 
confirmed
Incidence 
of Zika virus 
(suspected 
and 
confirmed) 
per 1000 
people per 
year
Incidence 
of Zika virus 
(confirmed) 
per 1000 
people per 
year
CZS 
cases
CZS per 
1000 births 
(2016/17)
A B A+B (A+B)/2D B/2D C C/2E×1000 D E
Brazil* 205 997 155 820 56 361 817 0.86 0.372 2952 0.507 209 428 2 911 930
Colombia 100 255 9717 91 109 972 1.13 0.099 248 0.190 48 860 652 112
Guatemala 4003 1054 79 5057 0.15 0.031 140 0.181 16 793 386 023
Dominican 
Republic
5248 336 93 5584 0.26 0.015 85 0.296 10 708 143 822
Puerto Rico – 36 871 0 36 871 10.02 10.016 47 0.892 1840 26 357
Mexico – 11 791 0 11 791 0.05 0.045 20 0.004 128 897 2 263 873
Costa Rica 21 9949 0 9970 1.02 1.019 19 0.137 4881 69 410
Panama 4786 1059 81 5845 0.72 0.130 17 0.113 4044 75 008
Trinidad and 
Tobago
– 722 0 722 0.26 0.264 17 0.475 1367 17 883
Ecuador 3722 3011 55 6733 0.20 0.091 14 0.025 16 505 283 020
Bolivia 2216 816 73 3032 0.14 0.037 14 0.027 10 970 255 713
Honduras 31 378 266 99 31 644 1.81 0.015 8 0.022 8727 184 312
Martinique 37 997 – 100 37 997 48.65 0.000 5 0.674 390 3711
Guadeloupe 32 250 28 99 32 278 35.05 0.030 5 0.570 460 4389
Argentina 536 276 66 812 0.01 0.003 5 0.003 44 059 716 322
El Salvador 12 467 3 99 12 470 1.00 0.000 4 0.018 6262 109 617
Suriname 2816 733 79 3549 3.19 0.659 4 0.203 555 9847
Guyana – 34 0 34 0.04 0.044 3 0.115 385 13 060
Nicaragua 751 614 55 1365 0.11 0.049 2 0.007 6184 137 772
Grenada 335 119 73 454 2.04 0.533 2 0.672 111 1487
Paraguay 106 14 88 120 0.01 0.001 2 0.008 6768 128 117
French Guiana 10 742 48 99 10 790 19.30 0.085 1 0.065 279 7663
Haiti 3077 – 100 3077 0.28 0.000 1 0.002 5424 247 025
Saint Martin 1580 200 88 1780 55.63 6.250 1 1.000 16 500
Barbados 672 137 83 809 1.39 0.234 1 0.196 291 2552
Venezuela 61 708 – 100 61 708 0.97 0.000 0 0 31 748 602 123
Jamaica 6958 186 97 7144 1.25 0.032 0 0 2846 35 164
Peru 5737 1293 81 7030 0.11 0.020 0 0 31 969 502 591
Curacao 4362 2020 68 6382 21.27 6.733 0 0 150 1668
Belize 1762 269 86 2031 2.74 0.362 0 0 371 7200
Cuba 1305 324 80 1629 0.07 0.014 0 0 11 439 115 921
Aruba 830 645 56 1475 6.44 2.816 0 0 114 1230
Dominica 1154 79 93 1233 8.33 0.533 0 0 74 721
Saint Vincent 
and the 
Grenadines
505 84 85 589 5.77 0.823 0 0 51 1634
Saint Kitts and 
Nevis
554 33 94 587 5.59 0.314 0 0 52 641
Antigua and 
Barbuda
537 25 95 562 2.97 0.132 0 0 94 1085
Bahamas 510 25 95 535 0.68 0.031 0 0 394 4055
Continued
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DISCUSSION
This study is the first comprehensive study in the Amer-
icas of the entire course of the Zika epidemic using the 
infectious disease surveillance reports together with 
the number of population births. The study demon-
strates again that the vast majority of CZS cases occurred 
in Brazil. In Brazil, 2952 CZS cases were reported, 
compared with a baseline of about 380 cases of micro-
cephaly expected over that 2- year period.16 The study has 
shown in addition a high epidemic intensity in some of 
the Caribbean islands. The phenomenon of a very high 
proportion of individuals on an island being infected 
has been noted for both Zika virus and other infections. 
Kucharski et al studied the outbreak of ZIKV from 2013 to 
2014 in French Polynesia and concluded that 94% of the 
population were infected during the outbreak.13 The first 
reported epidemic of Zika virus in the island of Yap in 
200717 reported over 70% of residents had been infected. 
Dengue shows a similar pattern of high infection rates on 
islands, and this also results in a more cyclical pattern of 
population infection every 12–15 years compared with 
the lower and more constant dengue virus infection rates 
in larger communities.18
Susceptibility to Zika virus infection varies hugely 
according to climatic, environmental and social factors. 
How, it would be expected that the risk of an infected 
Country
Zika virus infections† CZS
Population 
(’000) in 
2016/17
Annual 
births in 
2016/17‡Suspected
Confirmed 
(including 
imported)
% 
Suspected
Total 
suspected 
and 
confirmed
Incidence 
of Zika virus 
(suspected 
and 
confirmed) 
per 1000 
people per 
year
Incidence 
of Zika virus 
(confirmed) 
per 1000 
people per 
year
CZS 
cases
CZS per 
1000 births 
(2016/17)
Virgin Islands 
(USA)
400 56 87 456 4.43 0.543 0 0 51 1415
Sint Maarten 248 148 62 396 4.77 1.783 0 0 41 363
Saint Lucia 280 52 84 332 1.01 0.158 0 0 164 2103
Saint 
Barthelemy
270 61 81 331 36.78 6.777 0 0 4 72
Cayman 
Islands
229 30 88 259 2.25 0.260 0 0 57 642
Turks and 
Caicos Islands
197 25 88 222 2.13 0.240 0 0 52 518
Virgin Islands 
(UK)
74 53 58 127 1.84 0.768 0 0 34 266
Anguilla 30 23 56 53 1.56 0.676 0 0 17 155
Montserrat 18 5 78 23 2.30 0.500 0 0 5 46
Bonaire, St 
Eustatius and 
Saba
– 9 0 9 0.35 0.346 0 0 13 346
Total 548 623 239 063 70 787 686 3617
1. Brazil Ministry of Health case definition for confirmed cases of congenital syndrome associated with Zika virus infection includes confirmed and probable cases 
per PAHO’s case definition.
2. The number of confirmed congenital syndrome associated with Zika include two autochthonous cases and three imported cases.
3. The reported number of suspected cases of Zika virus infection are estimates. According to Santé publique France, the estimated number of suspected cases is 
the sum of the number of visits recorded by the Decentralised Centres of Prevention and Care and the estimated number of people who sought medical care from a 
general practitioner for this purpose. The estimate is based on data collected by the sentinel physician network.
4. The case reported by Santé publique France corresponds to a fetus with cerebral malformation of a mother infected with Zika.
5. In addition to the five reported cases of congenital syndrome, Santé publique France reported 16 fetuses with cerebral malformations of mothers infected with 
Zika.
6. Santé publique France reported 21 fetuses with cerebral malformations of mothers infected with Zika.
7. In addition to the one reported case of congenital syndrome, Santé publique France reported 18 fetuses with cerebral malformations of mothers infected with 
Zika.
*CZS cases in Brazil occurring in 2015 are included.
†PAHO/WHO case definitions for suspected and confirmed Zika virus infections is available at: http://www.paho.org/hq/index.php?option=com_
content&view=article&id=11117&Itemid=41532&lang=en.
‡Total births were estimated as twice the most recent birth years if data were not available for 2016 and 2017: Honduras (2012), Haiti (2013), Grenada (2014), 
Trinidad and Tobago (2015), El Salvador (2015) and Guyana (2015).
§Confirmed congenital syndrome associated with Zika virus infection case definition: live newborn who meets the criteria for a suspected case of 
congenital syndrome associated with Zika virus and Zika virus infection was detected in specimens of the newborn, regardless of detection of other 
pathogens. Case definitions for congenital syndrome associated with Zika virus infection is available at: http://www.paho.org/hq/index.php?option=com_
content&view=article&id=11117&Itemid=41532&lang=en.
CZS, congenital Zika syndrome; PAHO, Pan American Health Organization.
Table 1 Continued
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pregnancy resulting in CZS is likely to have a much small 
variation. The occurrence of discordant twins for CZS 
shows that ZIKV infection during pregnancy is not deter-
ministic for CZS phenotype and that other susceptibility 
factors might be involved.19 Comparing the calculated 
number of CZS cases per 1000 infected pregnent woman 
with the expected 4–60 CZS case per 1000 infected preg-
nant women, reveals the huge variations in testing and 
reporting of Zika virus infections in Latin America. Inter-
pretation of infectious disease reports should therefore 
be cautious. Although we found a clumping of countries 
around the expected 4–60 CZS per 1000 infected preg-
nant women, the infectious disease reports are clearly 
not suitable for such estimations which must come from 
properly designed epidemiological studies such as cohort 
studies. However, the potential imbalance due to suscep-
tibility factors is likely to be of a much smaller order of 
magnitude than the occurrence of under- reporting indi-
cated in this study.
A comparison between Brazil, Colombia and Puerto 
Rico is instructive to understand the complexity of 
comparing CZS figures between countries. The incidence 
of confirmed plus suspected Zika virus cases per 1000 
people varied >10- fold from 0.86 in Colombia, 1.12 in 
Brazil to 10 in Puerto Rico, while in contrast the prev-
alence of CZS per 1000 births varied <5- fold from 0.19 
in Colombia, to 0.51 in Brazil and 0.89 in Puerto Rico. 
In Colombia, termination of pregnancy was allowed in 
cases with CZS,20 thereby potentially decreasing the birth 
prevalence of CZS in Colombia relative to the infection 
rate. Brazil used a lower threshold for diagnosing micro-
cephaly and hence CZS at the beginning of the epidemic 
which may have inflated the earlier reports relative to 
other countries. All three countries were more likely to 
test and report Zika virus infections in pregnant women 
than in the general population. Calculating the number 
of CZS births per 1000 births to women infected with 
Zika virus (suspected or confirmed) results in values of 
12 in Colombia, 113 in Brazil and 12 in Puerto Rico. In 
addition to Brazil using a lower threshold for diagnosing 
microcephaly, at the start of the epidemic in Brazil preg-
nant women were not tested for Zika virus infection, 
but only judged to have been infected once the child 
was diagnosed with CZS, both of which would cause the 
number of CZS cases per infected pregnant women to be 
much higher. However, there may also be some under- 
reporting of CZS in Colombia and Puerto Rico compared 
with Brazil.
There are many factors influencing the reporting of 
both Zika virus and CZS. For Zika virus, reporting depends 
on the true rate of infection in the population, the 
proportion of symptomatic people with access to health-
care presenting at health centres, the policy as to which 
suspected infections should have laboratory confirmation 
(eg, in Brazil testing was restricted mainly to pregnant 
women), the difficulties of retrospective confirmation of 
infection as it is difficult to distinguish Zika from other 
flaviviruses outside the viraemic phase, and the exhaus-
tiveness of public health reporting mechanisms.
For CZS, reporting also depends on the proportion of 
affected babies/mothers with clinical signs of CZS tested 
for Zika virus, and the proportion of affected pregnan-
cies who proceed to live birth. In addition to the above 
factors, and particularly the difficulty of confirming fetal 
Zika virus infection after birth, there are issues with the 
consistency of diagnoses of microcephaly, and with the 
reporting of terminations of pregnancy where they are 
legal. Inconsistencies in microcephaly diagnosis have 
been identified across European, US and South Amer-
ican congenital anomaly registries prior to the Zika 
epidemic.10 21 22 In March 2016, WHO issued new guid-
ance as to the diagnoses of microcephaly ‘Neonates 
with a head circumference >2 SD below the mean are 
considered to have microcephaly. Neonates with a head 
Figure 1 Congenital Zika syndrome (CZS) cases per 1000 births compared with the incidence of Zika virus infections.
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Table 2 Zika virus infections in pregnant women in countries in the South and Central Americas, Mexico and the Caribbean, 
2015–2017 and the number of CZS cases per 1000 pregnant women with Zika virus and number of pregnant women with Zika 
virus per 1000 births
Country
CZS cases 
(table 1)
Reported number of 
pregnant women with Zika 
virus Date 
pregnancies 
reported (week/
year)
CZS cases per 
1000 pregnant 
women with Zika 
virus suspected 
or confirmed*
Number of pregnant 
women with Zika 
virus suspected or 
confirmed per 1000 
births*
Zika virus 
suspected or 
confirmed
Zika virus 
confirmed
C G H C/G×1000 G/E (table 1)×1000
Brazil 2952 26 066 11 546 22/2017 113.3 4.5
Colombia 248 19 993 6365 33/2017 12.4 15.3
Guatemala 140 1414 341 31/2017 99.0 1.8
Dominican Republic 85 966 271 30/2017 88.0 3.4
Puerto Rico 47 NR 4047 35/2017 11.6 76.8
Mexico 20 NR 5667 34/2017 3.5 1.3
Costa Rica 19 NR 210 33/2017 90.5 1.5
Panama 17 212 86 35/2017 80.2 1.4
Trinidad and Tobago 17 NR 463 8/2017† 36.7 12.9
Ecuador 14 NR 912 32/2017 15.4 1.6
Bolivia 14 NR 189 24/2017 74.1 0.4
Honduras 8 681 125 33/2017 11.7 1.8
Martinique 5 NR 830 30/2017 6.0 111.8
Guadeloupe 5 NR 815 30/2017 6.1 92.8
Argentina 5 NR 5 35/2017 1000.0 0.003
El Salvador 4 391 NR 33/2017 10.2 1.8
Suriname 4 NR NR 35/2017
Guyana 3 NR NR 35/2017
Nicaragua 2 NR 1117 1/2017† 1.8 4.1
Grenada 2 NR NR 22/2017
Paraguay 2 31 3 28/2017 64.5 0.1
French Guiana 1 NR 2211 36/2017 0.5 144.3
Haiti 1 22 NR 21/2016† 45.5 0.04
Saint Martin 1 NR 48 30/2017 20.8 48.0
Barbados 1 NR 32 32/2017 31.3 6.3
Venezuela 0 3463 NR 12/2017 0 2.9
Jamaica 0 712 78 12/2017 0 10.1
Peru 0 NR 279 33/2017 0 0.3
Curacao 0 NR 30 44/2016† 0 9.0
Belize 0 NR 1 20/2016† 0 0.1
Cuba 0 NR NR 35/2017
Aruba 0 NR NR 35/2017
Dominica 0 13 10 38/2016† 0 9.0
Saint Vincent and the 
Grenadines
0 3 1 35/2016† 0 0.9
Saint Kitts and Nevis 0 NR NR 35/2017
Antigua and Barbuda 0 16 6 27/2017 0 7.4
Bahamas 0 NR NR 35/2017
Virgin Islands (USA) 0 NR 286 34/2017 0 101.1
Continued
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circumference >3 SD below the mean should be consid-
ered to have severe microcephaly’. (Assessment of infants 
with microcephaly in the context of Zika virus Interim 
guidance 4 March 2016 ‘WHO/ZIKV/MOC/16.3 Rev.1’ 
http:// www. who. int/ csr/ resources/ publications/ zika/ 
assessment- infants/ en/.) Many countries had been using 
Country
CZS cases 
(table 1)
Reported number of 
pregnant women with Zika 
virus Date 
pregnancies 
reported (week/
year)
CZS cases per 
1000 pregnant 
women with Zika 
virus suspected 
or confirmed*
Number of pregnant 
women with Zika 
virus suspected or 
confirmed per 1000 
births*
Zika virus 
suspected or 
confirmed
Zika virus 
confirmed
Sint Maarten 0 10 1 35/2017 0 13.8
Saint Lucia 0 84 39 41/2016† 0 20.0
Saint Barthelemy 0 NR 11 30/2017 0 76.4
Cayman Islands 0 NR NR 35/2017
Turks and Caicos 
Islands
0 NR NR 35/2017
Virgin Islands (UK) 0 NR NR 35/2017
Anguilla 0 NR NR 35/2017
Montserrat 0 NR NR 35/2017
Bonaire, St Eustatius 
and Saba
0 NR NR 35/2017
Total 3617 54 077 36 025
*Numbers of pregnancies suspected or confirmed used unless this is not reported. In this case, number of confirmed pregnancies is used.
†Potentially incomplete data on infected pregnancies due to early reporting dates.
NR, not reported.
Table 2 Continued
Figure 2 Number of congenital Zika syndrome (CZS) cases per 1000 infected pregnancies (95% CI).
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a definition of >3 SD below the mean for microcephaly. 
This change in definition was likely to have greatly 
increased the numbers of microcephaly diagnoses made. 
At the start of the CZS epidemic, many countries did not 
have the resources to diagnose cases as soon as they were 
born.23
Despite the evidence of under- reporting, other 
researchers have attempted to use these published figures 
to investigate the Zika virus epidemic. A study by Hay et 
al24 used the publicly available data from Brazil and 
Colombia to attempt to determine the gestational age risk 
of ZIKV infection and microcephaly. They concluded that 
the currently available surveillance data were insufficient 
to use in estimating risks of microcephaly from ZIKV 
infection.
Our analyses of CZS per 1000 births and the number of 
CZS per 1000 births to pregnant women with Zika virus 
provides considerable added value for estimating the 
burden of disease, including highlighting areas of data 
inconsistency, and we suggest this should be added to 
routine PAHO output, and to WHO output in general in 
tracking future epidemics. This will also make it easier 
to assess the impact of preventive interventions (eg, to 
prevent infection among pregnant women during an 
epidemic). Countries also need to report centrally how 
they ascertain cases of both Zika virus and CZS in order 
Figure 3 Zika virus infection in pregnancy compared with incidence of Zika virus in the population.
Table 3 Comparison of cumulative numbers of CZS reported to PAHO/WHO and those predicted by Zhang et al in spread of 
Zika virus in Latin America and the Caribbean14
Predicted number by December 2017
Reported to PAHO/
WHO by January 
2018
First trimester risk (per 1000)
9.5 21.9 45.2
Brazil 1297 (1190–1428) 2991 (2744–3291) 6173 (5664–6792) 2952
Colombia 219 (194–248) 504 (447–572) 1041 (922–1180) 248
Mexico 314 (226–367) 723 (522–845) 1493 (1077–1744) 20
Puerto Rico 19 (13–26) 43 (29–60) 86 (60–124) 47
El Salvador 39 (32–47) 91 (75–108) 187 (154–223) 4
Honduras 144 (124–163) 332 (286–376) 686 (590–775) 8
Haiti 316 (276–357) 728 (637–824) 1502 (1315–1700) 1
Venezuela 271 (237–308) 624 (546–711) 1288 (1127–1468) 0
CZS, congenital Zika syndrome; PAHO, Pan American Health Organization.
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to help interpretation, as this information is currently not 
publicly available in a coordinated manner. These issues 
have recurred again in a different form in COVID-19 
reporting, where WHO figures lack population denom-
inators, and lack information about testing regimes in 
different countries, leading to potentially misleading 
interpretations of differences between countries.
CZS is likely to identify only those children severely 
affected and identifiable at birth. It is believed that many 
further thousands of children will suffer some effects 
despite appearing healthy at birth. These figures show 
the cost of the Zika virus epidemic across the South and 
Central Americas, Mexico and the Caribbean and high-
light that many areas will need considerable resources to 
cope with the long- term effects in children.
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